Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Operating Margin: 2010-2025

Historic Operating Margin for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to -10.71%.

  • Heron Therapeutics' Operating Margin rose 288.00% to -10.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 1985.00%. This contributed to the annual value of -7.99% for FY2024, which is 7908.00% up from last year.
  • Latest data reveals that Heron Therapeutics reported Operating Margin of -10.71% as of Q3 2025, which was down 143.40% from -4.40% recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Operating Margin registered a high of 10.23% during Q4 2024, and its lowest value of -269.43% during Q2 2021.
  • For the 3-year period, Heron Therapeutics' Operating Margin averaged around -36.04%, with its median value being -13.84% (2024).
  • Its Operating Margin has fluctuated over the past 5 years, first tumbled by 5,272bps in 2021, then spiked by 19,141bps in 2022.
  • Quarterly analysis of 5 years shows Heron Therapeutics' Operating Margin stood at -259.20% in 2021, then spiked by 19,141bps to -67.79% in 2022, then soared by 3,793bps to -29.85% in 2023, then spiked by 4,009bps to 10.23% in 2024, then surged by 288bps to -10.71% in 2025.
  • Its Operating Margin was -10.71% in Q3 2025, compared to -4.40% in Q2 2025 and 8.11% in Q1 2025.